Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Seminars in immunopathology - 1 Jan 2019

Hasselbalch Hans Carl, Holmström Morten Orebo

Abstract excerpt

The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in several cancer types but unfortunately not being explored sufficiently due to a high toxicity profile when using non-pegylated IFN-alpha2 or high dosages or due to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease Progression
Share to Immunologic Surveillance

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inflammation

Share to Interferon-alpha

Share to Myeloproliferative Disorders

Share to Neoplasm, Residual

Share to Polycythemia Vera

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 30203226
DOI: 10.1007/s00281-018-0700-2
PMCID: PMC6323070

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?PMID 30203226Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms.Semantic proximity Read ↗

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read ↗

Mutations, inflammation and phenotype of myeloproliferative neoplasmsSemantic proximity Read ↗

Interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms favorably impacts deregulation of oxidative stress genes and antioxidative defense mechanisms.Semantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

JAK2 inhibitors for myeloproliferative neoplasms: what is next?Semantic proximity Read ↗

Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.Semantic proximity Read ↗

The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms.Semantic proximity Read ↗

Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alphaSemantic proximity Read ↗

Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.